Morgan Stanley Downgrades IMS Health (RX) to Underweight
More News related to RX
- BioSyent Releases Financial Results-Third Quarter 2008
- BioSyent Releases Financial Results-Third Quarter 2008
- New Study Highlights Rising Number of Type 2 Diabetes Patients in U.S., Increasing Complexity of Treatments
- Raymond James Downgrades IMS Health (RX) to Outperform
- IMS to Present at Credit Suisse Conference on November 12 at 10:30 a.m. MST
More News related to Downgrades
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Morgan Stanley downgrades IMS Health (NYSE: RX) from Equalweight to Underweight. Price target $18.
IMS Health Incorporated (IMS) is a provider of market intelligence to the pharmaceutical and healthcare industries.
Related Categories
DowngradesStocks Mentioned
-0.49Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
